Zheng Wang1, Qingyong Ma, Pei Li, Huanchen Sha, Xuqi Li, Jun Xu. 1. Department of Hepatobiliary Surgery, The First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, P.R. China. qyma56@mail.xjtu.edu.cn or xjxpx@189.cn.
Abstract
AIM: The stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis and Wingless and INT-1 (Wnt)/β-catenin pathway has been related to cancer progression. The aim of this study was to investigate the expression of CXCR4 and β-catenin in pancreatic cancer. PATIENTS AND METHODS: A total of 48 pancreatic cancer samples and 8 normal pancreatic tissues were selected to detect CXCR4 and β-catenin expression by an immunohistological technique. Spearman and Chi-square analyses were used to study the relation between the protein expression and clinical characteristics. Survival analysis was evaluated by the Kaplan-Meier product limit method. RESULTS: The proportions of CXCR4 and β-catenin expression on pancreatic cancer cells were significantly higher than in normal pancreas tissues. There was a significant difference in CXRC4 expression levels, lymph node metastasis and TNM stage. Clinical Significance was observed for β-catenin expression and lymph node metastasis; Kaplan-Meier curves suggested that clinical prognosis is poor for patients expressing CXCR4. Multivariate analysis showed that CXCR4 expression was an independent prognostic factor for pancreatic cancer. CONCLUSION: Both CXCR4 and β-catenin are abnormally expressed in pancreatic cancer. CXCR4 may be an important marker for pancreatic cancer progression.
AIM: The stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) axis and Wingless and INT-1 (Wnt)/β-catenin pathway has been related to cancer progression. The aim of this study was to investigate the expression of CXCR4 and β-catenin in pancreatic cancer. PATIENTS AND METHODS: A total of 48 pancreatic cancer samples and 8 normal pancreatic tissues were selected to detect CXCR4 and β-catenin expression by an immunohistological technique. Spearman and Chi-square analyses were used to study the relation between the protein expression and clinical characteristics. Survival analysis was evaluated by the Kaplan-Meier product limit method. RESULTS: The proportions of CXCR4 and β-catenin expression on pancreatic cancer cells were significantly higher than in normal pancreas tissues. There was a significant difference in CXRC4 expression levels, lymph node metastasis and TNM stage. Clinical Significance was observed for β-catenin expression and lymph node metastasis; Kaplan-Meier curves suggested that clinical prognosis is poor for patients expressing CXCR4. Multivariate analysis showed that CXCR4 expression was an independent prognostic factor for pancreatic cancer. CONCLUSION: Both CXCR4 and β-catenin are abnormally expressed in pancreatic cancer. CXCR4 may be an important marker for pancreatic cancer progression.
Authors: Lu Liu; Qiaoming Zhi; Meng Shen; Fei-Ran Gong; Binhua P Zhou; Lian Lian; Bairong Shen; Kai Chen; Weiming Duan; Meng-Yao Wu; Min Tao; Wei Li Journal: Oncotarget Date: 2016-07-26
Authors: Andrew K Kwegyir-Afful; Francis N Murigi; Puranik Purushottamachar; Vidya P Ramamurthy; Marlena S Martin; Vincent C O Njar Journal: Oncotarget Date: 2016-12-24